3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
1
Conditions
Arthritis, Rheumatoid
2
Lymphoma, Follicular
1
Interventions
Methotrexate
8
Adalimumab
7
Etanercept
5
tocilizumab
4
Rituximab
4
tofacitinib
3
Abatacept
3
olokizumab
2
golimumab
2
Tumor Necrosis Factor Inhibitors
2
Antirheumatic Agents
2
upadacitinib
1
secukinumab
1
sarilumab
1
mavrilimumab
1
baricitinib
1
andecaliximab
1
Vitamin D
1
Vaccines
1
TACI receptor-IgG Fc fragment fusion protein
1
Syringes
1
Sulfasalazine
1
Saline Solution
1
Leflunomide
1
Hydroxychloroquine
1
Herpes Zoster Vaccine
1
Folic Acid
1
Fish Oils
1
Fatty Acids, Omega-3
1
Eicosapentaenoic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Arthritis, Rheumatoid
×
olokizumab
×
Clear all
NCT03120949
2023-10-12
CREDO 4
R-Pharm
Phase 3
Completed
2,106 enrolled
30 charts
NCT02760433
2023-09-21
CREDO 3
R-Pharm
Phase 3
Completed
368 enrolled
21 charts